The history of Viagra, formerly marketed by copyright, presents a intricate case study for backers considering the pharmaceutical sector. Despite its early success and impact of billions in earnings , the intellectual property end has opened the way for generic medications, greatly diminishing profit opportunities. This shift raises concerns about